Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Chembio wins FDA approval for extended age range for HIV rapid tests
Lowering the testing age claim from 18 years of age to 13 is consistent with the latest US Centers for Disease Control (CDC) recommendations that routine screening for
Lowering the testing age claim from 18 years of age to 13 is consistent with the latest US Centers for Disease Control (CDC) recommendations that routine screening for
Mr Peizer will remain on the board, and Mr Goldberger will remain on the board of the company’s operating subsidiary. Mr McCrann was recently senior vice president of
The Perseus clinical program has enrolled nearly 1,500 patients at 100 US and international centers since July 2007, and will compare the Taxus Element stent to the prior-generation
Drug manufacturers also promised to add language to medications containing antihistamine products to warn parents not to drug their children for the purposes of helping them sleep. Recently,
The primary endpoint was defined as the proportion of baminercept-treated patients who achieved an ACR50 response, a standard measure of disease improvement in rheumatoid arthritis (RA), compared to
The application was based on a study showing that the deltoid and gluteal injections of Risperdal Consta were bioequivalent routes of administration and thus interchangeable. An additional study
The new NimbleGen comparative genomic hybridization (CGH) HD2 arrays follow on the heals of Roche NimbleGen’s recent launch of CGH 4x72K arrays, aimed at improving sample throughput for
Pathway Medical Technologies co-founder and previous CEO Tom Clement, who has been instrumental in leading the company through the initial stages to commercialization, will continue as an officer
In this role, Ms McCoy succeeds Christine Poon, who announced plans to retire from the company on March 1, 2009. Ms McCoy joined Johnson & Johnson (J&J) in
Under the purchase agreement, Natus will acquire essentially all the trading assets of BrainZ for a cash price of NZD$1.3 million, including the BRM2 and BRM3 monitoring devices,